Semaglutide use before single-level lumbar fusion associated with fewer readmissions and 90-day costs
Semaglutide use before single-level lumbar fusion is associated with reduced 90-day readmissions and costs without increasing complication risk.
Authors
- Brian T. Ford
- Ahmed K. Emara (ORCID: https://orcid.org/0000-0002-8421-7340)
- Jad Bou Monsef (ORCID: https://orcid.org/0000-0001-5614-3690)
- Mitchell K. Ng (ORCID: https://orcid.org/0000-0002-5831-055X)
- Ariel N. Rodriguez (ORCID: https://orcid.org/0000-0002-1319-4831)
- Afshin E. Razi (ORCID: https://orcid.org/0000-0002-3443-4582)
- Jonathan Dalton (ORCID: https://orcid.org/0000-0002-7452-2712)
- Paul G. Mastrokostas (ORCID: https://orcid.org/0000-0002-1196-517X)
- Leonidas E. Mastrokostas (ORCID: https://orcid.org/0009-0006-8926-3502)
- Jacquelyn J Xu (ORCID: https://orcid.org/0009-0004-2336-439X)
- Christopher K. Kepler
- Abigail Razi (ORCID: https://orcid.org/0009-0008-1582-0809)
- Alan S. Hilibrand
- Alexander R. Vaccaro
Institutions
- Cleveland Clinic (US)
- Maimonides Medical Center (US)
- University of Connecticut (US)
- University of Hartford (US)
- SUNY Downstate Health Sciences University (US)
- Thomas Jefferson University Hospital (US)
- Rothman Orthopaedics (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
Publication Details
- Journal
- Journal of Craniovertebral Junction and Spine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.4103/jcvjs.jcvjs_156_25
- Primary Topic
- Spine and Intervertebral Disc Pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00